21.1 C
New York
Wednesday, June 29, 2022

Caladrius Biosciences Inc (CLBS) Stock Rises 23% Today, But Why?

Caladrius Biosciences Inc (CLBS) stock price is increasing significantly in the pre-market session on Wednesday 10th March 2021. The stock price has been increased by 23.50% as of this writing.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.


The reason behind the positive trend

The stock analysts at Brookline Capital Management increased their estimated price from $7.00 to $10.00.  Brookline Capital Management’s price target suggests a potential upside of 446.45% from the company’s current price. Caladrius Biosciences currently has a consensus rating of “Buy” and a consensus target price of $8.06.

Orphan Drug status for CLBS12 from FDA

On March 8, 2021, the Caladrius Biosciences announced that their CD34+ cell therapy, CLBS12, the product has received orphan drug designation from the U.S. Food and Drug Administration (“FDA”). The above-mentioned drug is used to treat Buerger’s disease, a condition which is related to critical limb ischemia (CLI) and it has no approved treatments to date in the U.S.

President and Chief Executive Officer of Caladrius. David J. Mazzo, PhD expresses his pleasure in the approval of CLBS12 as an orphan drug designation. He further said that their drug has shown strong results in Japan for the treatment of Buerger’s Disease. The company is now looking to discuss the next step with the FDA, which is the registration of CLBS12 in the USA.

The company announced its Q4 and full-year 2020 financial results on February 25, 2021.

Fourth Quarter and Full Year 2020 Financial Highlights

The company spent 2.9 million in the fourth quarter on Research and development expenses and $9.3 million for the year ended December 31, 2020. The company reported a net loss of $8.1 million for the year ended December 31, 2020, compared to $19.4 million for the year 2019. The company spent $2.5 million in General and administrative expenses in the fourth quarter and $9.9 million for the year ended December 31, 2020. The company reported earnings of $0.28 per share for the quarter, missing the analyst’s estimates of ($0.27) by ($0.01).

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

Related Articles


Please enter your comment!
Please enter your name here

Latest Articles




Download Free eBook For

The 5 Best Growth Stocks 2022

100% free. stop anytime no spam